Acute and sub-acute effect of ferric carboxymaltose on inflammation and adhesion molecules in patients with predialysis chronic renal failure;Efecto agudo y subagudo de la carboximaltosa férrica sobre la inflamación y moléculas de adhesión en pacientes con insuficiencia renal crónica prediálisis

Nefrologia

Volumn 33, Issue 3, 2013, Pages 355-361

  Prats, Merche ^a   Font, Ramon ^a   García Ruiz, Carmen ^a   Cabré, Carmen ^a   Muñoz Cortés, Mónica ^b   Rosa Nogues M ^b   Jariod, Manel ^a   Romeu, Marta ^b   Martínez Vea, Alberto ^a  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

Adhesion molecules; Chronic kidney disease; Ferric carboxymaltose; Inflammation

Indexed keywords

CELL ADHESION MOLECULE; DRUG DERIVATIVE; FERRIC CARBOXYMALTOSE; FERRIC ION; MALTOSE;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; IRON DEFICIENCY ANEMIA; MALE; PROSPECTIVE STUDY;

AGED; ANEMIA, IRON-DEFICIENCY; CELL ADHESION MOLECULES; FEMALE; FERRIC COMPOUNDS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALE; MALTOSE; PROSPECTIVE STUDIES;

EID: 84878024210     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2013.Jan.11774     Document Type: Article

References (36)

1. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002;162:1401.
2. Akins PT, Glenn S, Nemeth PM, Derdeyn CP. Carotid artery thrombus associated with severe iron deficiency anemia and thrombocytosis. Stroke 1996;27:1002-5.
3. Hartfield DS, Lowry NJ, Keene DL, Yager JY. Iron deficiency: a cause of stroke in infants and children. Pediatr Neurol 1997;16:50-3.
4. De Caterina R, Basta G, Lazzerini G, Dell'Omo G, Petrucci R, Morale M. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2646-54.
5. Suliman M, Qureshi R, Heimburger O, Lindholm B, Stenvinkel P. Soluble adhesion molecules in end-stage renal disease: a predictor of outcome. Nephrol Dial Transplant 2006;21:1603-10.
6. Stinghen AE, Gonçalves SM, Martines EG, Nakao LS, Riella MC, Aita CA, et al. Increased plasma and endothelial cell expression of chemokines and adhesion molecules in chronic kidney disease. Nephron Clin Pract 2009;111:c117-26.
7. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005;16 Suppl 1:S83-8.
8. Yuksel A, Kebapcilar L, Erdur E, Bozkaya G, Sari I, Alacacioglu A, et al. The Effect of iron treatment on adhesion molecules in patients with iron deficiency anemia. Biol Trace Elem Res 2010;137:317-23.
9. Agarwal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int 2006;69:1259-63.
10. Kamanna VS, Ganji SH, Shelkovnikov S, Norris K, Vaziri ND. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am J Nephrol 2012;35:114-9.
11. Jairam A, Das R, Aggarwal PK, Kohli HS, Gupta KL, Sakhuja V, et al. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian J Nephrol 2010;20:125-31.
12. Malindretos P, Sarafidis PA, Rudenco I, Raptis V, Makedou K, Makedou A, et al. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran. Am J Nephrol 2007;27:572-9.
13. Borawski J, Gozdzikiewicz J, Abramowicz P, Naumnik B, Mysliwiec M. Endothelial injury markers with high-dose intravenous iron therapy in renal failure. Clin Appl Thromb Hemost 2004;10:403-6.
14. Kumbasar A, Gursu M, Kaya C, Ozturk S, Ergen A, Kemik A, et al. The effect of different doses and types of intravenous iron on oxidative stress and inflammation in hemodialysis patients. J Nephrol 2012;25(5):825-32.
15. Bolaños L, González-Juanatey C, Testa A, Ranero R. Intravenous iron sucrose does not impair sonographic brachial vasodilation in peritoneal dialysis patients. Adv Perit Dial 2008;24:90-5.
16. OzKurt S, Ozenc F, Degirmenci NA, Temiz G, Musmul A, Sahin G, et al. Acute and subacute effects of EV iron sucrose on endothelial functions in hemodialysis patients. Ren Fail 2012;34:1-6.
17. Martin-Malo A, Merino A, Carracedo J, Alvarez-Lara MA, Ojeda R, Soriano S, et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012;27:2465-71.
18. Sonnweber T, Theurl I, Seifert M, Schroll A, Eder S, Mayer G, et al. Impact of iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant 2011;26:977-87.
19. Toblli JE, Cao G, Olivieri L, Angerosa M. Comparison of the renal , cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant 2010;25:3631-40.
20. Barton Pai A, Conner TA. Oxidative stress and inflammation in chronic kidney disease: role of intravenous iron and vitamin D. J Pharmacy Practice 2008;21:214-24.
21. De Vecchi A, Novembrino C, Lonati S, Hipólito S, Bamonti F. Two different modalities of iron gluconate i.v. administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients. Nephrol Dial Transplant 2007;22:1709-13.
22. Toblli JE, Cao G, Oliveri L, Angerosa M. Assessment of the extent of oxidative stress induced by intravenous ferumoxytol, ferric carboxymaltose, iron sucrose and iron dextran in a nonclinical model. Arzneimittelforschung 2011;61:399-410.
23. Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung 2010;60:345-53.
24. Sood MM, Oudit G, Mohammadi H, Huang H, Lok CE. Effects of parenteral iron on inflammation and the myocardium in hemodialysis patients. Hemodial Int 2008;12:362-8.
25. Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007;191:397-402.
26. Ross R. Atherosclerosis is and inflammatory disease. Am Heart J 1999;138:419-20.
27. Shen L, Lu G, Dong N, Jiang L, Ma Z, Ruan C. Von Willebrand factor, ADAMTS13 activity, TNF-a and their relationships in patients with chronic kidney disease. Exp Ther Med 2012;3:530-4.
28. Ozkok A, Elcioglu OC, Cukadar T, Bakan A, Sasak G, Atilgan KG, et al. Low serum pancreatic enzyme levels predict mortality and are associated with malnutrition-inflammation-atherosclerosis syndrome in patients with chronic kidney disease. Int Urol Nephrol 2012 Aug 2. [Epub ahead of print].
29. Yadav AK, Lal A, Jha V. Cytotoxic CD4CD28(null) T Lymphocytes, Systemic Inflammation and Atherosclerotic Risk in Patients with Chronic Kidney Disease. Nephron Clin Pract 2012;120:c185-c193.
30. Kourea K, Parissis JT, Framakis D, Panou F, Paraskevaidis I, Venetsanou K, et al. Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis 2008;199:215-21.
31. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003;64:572-8.
32. Wong BW, Meredith A, Lin D, McManus BM. The biological role of inflammation in atherosclerosis. Can J Cardiol 2012;28:631-41.
33. Hot A, Lavocat F, Lenief V, Miossec P. Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-a on endothelial cells. Ann Rheum Dis 2012 Aug 21. [Epub ahead of print].
34. Brili S, Tousoulis D, Antonopoulos AS, Antoniades C, Htazis G, Bakogiannis C, et al. Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta. Heart 2012;98:325-9.
35. Leeuwenberg JF, Smeets EF, Neefjes JJ, Shaffer MA, Cinek T, Jeunhomme TN, et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543-9.
36. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252:283-94